Table 1.
Results of immune checkpoint inhibitor trials in head and neck squamous cell carcinoma (HNSCC).
| Relapsed/Metastatic Pretreated HNSCC | ||||
|---|---|---|---|---|
| Study | Phase | Treatment | Response | Overall Survival |
| CheckMate 141 | 3 | Nivolumab vs. investigator’s choice | 13 vs. 6% | 17 vs. 6% at 2 years |
| KEYNOTE 012 | 1b | Pembrolizumab | 18% | Median: 8 months |
| KEYNOTE 055 | 2 | Pembrolizumab | 16% | Median: 8 months |
| KEYNOTE 040 | 3 | Pembrolizumab vs. investigator’s choice | 15 vs. 10% | Median: 8.4 months vs. 6.9 months |
| First-line therapy in metastatic HNSCC | ||||
| KEYNOTE 048 | 3 | Pembrolizumab vs. pembrolizumab + chemo vs. EXTREME regimen |
17 vs. 36 vs. 36% | Pembrolizumab vs. EXTREME regimen*: 14.9 vs. 10.7 months for CPS > 20, 12.3 vs. 10.3 months for CPS > 1 Pembrolizumab + chemo vs. EXTREME regimen: 13 vs. 10.7 months |
| PDL-1 plus CTLA-4 blocker combination in pretreated metastatic HNSCC | ||||
| CONDOR | 2 | Durvalumab + Tremelimumab vs. Durvalumab monotherapy vs. Tremelimumab monotherapy |
8 vs. 9 vs. 2% | 7.6 vs. 6 vs. 5.5 months |
| CheckMate 651 | 3 | Nivolumab + Ipilimumab vs. EXTREME regimen | Results awaited | Results awaited |
| CheckMate 714 | 2 | Nivolumab + Ipilimumab vs. Nivolumab | Results awaited | Results awaited |
* EXTREME regimen: Phase 3 Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer Trial—Regimen containing 5-fluorouracil + platinum (cisplatin or carboplatin) +/− cetuximab.